A novel thieno[2,3‐ d ]pyrimidine derivative inhibiting vascular endothelial growth factor receptor‐2: A story of computer‐aided drug discovery
Drug Development Research · 2023
DOI: 10.1002/ddr.22083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2023. Verfasst von Eman A Sobh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Shibin-Elkom, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Princess Nourah Bint Abdulrahman University.
Abstract (Originalsprache)
Following the pharmacophoric features of vascular endothelial growth factor receptor 2 (VEGFR‐2) inhibitors, a novel thieno[2,3‐ d ]pyrimidine derivative has been designed and its activity against VEGFR‐2 has been demonstrated by molecular docking studies that showed an accurate binding mode and an excellent binding energy. Furthermore, the recorded binding was confirmed by a series of molecular dynamics simulation studies, which also revealed precise energetic, conformational, and dynamic changes. Additionally, molecular mechanics with generalized Born and surface area solvation and polymer‐induced liquid precursors studies were conducted and verified the results of the MD simulations. Next, in silico absorption, distribution, metabolism, excretion, and toxicity studies have also been conducted to examine the general drug‐like nature of the designed candidate. According to the previous results, the thieno[2,3‐ d ]pyrimidine derivative was synthesized. Fascinatingly, it inhibited VEGFR‐2 (IC 50 = 68.13 nM) and demonstrated strong inhibitory activity toward human liver (HepG2), and prostate (PC3) cell lines with IC 50 values of 6.60 and 11.25 µM, respectively. As well, it was safe and showed a high selectivity index against normal cell lines (WI‐38). Finally, the thieno[2,3‐ d ]pyrimidine derivative arrested the growth of the HepG2 cells at the G2/M phase inducing both early and late apoptosis. These results were further confirmed through the ability of the thieno[2,3‐ d ]pyrimidine derivative to induce significant changes in the apoptotic genes levels of caspase‐3, caspase‐9, Bcl‐2 associated X‐protein, and B‐cell lymphoma 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Menoufia University, Menoufia, Shibin-Elkom, Egypt.
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
- Biophysics Department, Faculty of Science, Cairo University, Cairo, Egypt.
- Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
ORCID-Profile: Mohammed A Dahab, Ibrahim H Eissa
Förderung
- Princess Nourah Bint Abdulrahman University
Zitieren
APA
Sobh, E. A., Dahab, M. A., Elkaeed, E. B., Alsfouk, B. A., Ibrahim, I. M., Metwaly, A. M., & Eissa, I. H. (2023). A novel thieno[2,3‐ d ]pyrimidine derivative inhibiting vascular endothelial growth factor receptor‐2: A story of computer‐aided drug discovery. Drug Development Research. https://doi.org/10.1002/ddr.22083
Vancouver
Sobh EA, Dahab MA, Elkaeed EB, Alsfouk BA, Ibrahim IM, Metwaly AM, et al. A novel thieno[2,3‐ d ]pyrimidine derivative inhibiting vascular endothelial growth factor receptor‐2: A story of computer‐aided drug discovery. Drug Development Research. 2023. doi:10.1002/ddr.22083
BibTeX
@article{Sobh2023,
author = {Sobh, Eman A and Dahab, Mohammed A and Elkaeed, Eslam B and Alsfouk, Bshra A and Ibrahim, Ibrahim M and Metwaly, Ahmed M and Eissa, Ibrahim H},
title = {A novel thieno[2,3‐ d ]pyrimidine derivative inhibiting vascular endothelial growth factor receptor‐2: A story of computer‐aided drug discovery},
journal = {Drug Development Research},
year = {2023},
doi = {10.1002/ddr.22083}
}
EUVIMED